Prosecution Insights
Last updated: April 19, 2026

Examiner: CRUM, MARY ABOU NADER

Tech Center 1600 • Art Units: 1657

This examiner grants 41% of resolved cases

Performance Statistics

41.0%
Allow Rate
-19.0% vs TC avg
120
Total Applications
+68.3%
Interview Lift
1287
Avg Prosecution Days
Based on 78 resolved cases, 2023–2026

Rejection Statute Breakdown

7.7%
§101 Eligibility
10.8%
§102 Novelty
38.6%
§103 Obviousness
23.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17652464 PROBIOTIC THERAPIES FOR SOCIAL DEFICIT AND STRESS RESPONSE Non-Final OA California Institute of Technology
17410360 PROBIOTICS AND PROBIOTIC COMPOSITIONS HAVING MODIFIED CARBOHYDRATE METABOLISM Final Rejection UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
17502595 SYSTEM AND METHOD FOR BIOREMEDIATION OF SOIL Non-Final OA The Trustees of Columbia University in the City of New York
17971072 MICROBIOME TRANSPLANTATION FOR OSTEOARTHRITIS THERAPY Final Rejection The Board of Regents of the University of Oklahoma
17757963 CONTROL OF HISTAMINE TO PROMOTE HEALTH AND CONTROL ENTEROCOLITIS USING PROBIOTIC COMPOSITIONS AND/OR HISTAMINE DEGRADING ENZYMES Non-Final OA Iowa State University Research Foundation, Inc.
17059932 PARENTERAL NUTRITION FORMULATION Final Rejection BAXTER HEALTHCARE SA
17921788 COMPOSITION FOR IMPROVING IMMUNITY Final Rejection The Chinese University of Hong Kong
17266717 MICROORGANISM MIXTURES, MOLECULES DERIVED THEREFROM, AND METHODS OF USE THEREOF Non-Final OA B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY
17618927 Alpha-Amylase Variants Final Rejection Novozymes A/S
17601019 Liquid Dishwashing Detergent Compositions Non-Final OA Novozymes A/S
17258863 SUPPORTED PLANT PLASMA MEMBRANE LIPID BILAYER ON-A-CHIP Non-Final OA Cornell University
17737884 LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES Final Rejection Arcturus Therapeutics, Inc.
17283287 NUTRITIONAL COMPOSITION COMPRISING 2'FUCOSYLLACTOSE AND DIETARY BUTYRATE Non-Final OA N.V. Nutricia
17587166 PSEUDOMONAS CHLORORAPHIS SPECIES AND ITS USE IN THE CONTROL OF DISEASES CAUSED BY BACTERIA AND FUNGI Non-Final OA UWM RESEARCH FOUNDATION, INC.
18051017 COMPOSITION FOR IMPROVING GUT MICROBIOTA AND METHOD FOR IMPROVING GUT MICROBIOTA WITH THE COMPOSITION THEREOF Non-Final OA TCI CO., LTD.
17916005 NOVEL DEINOCOCCUS RADIODURANS STRAIN, EXOPOLYSACCHARIDE DERIVED THEREFROM, AND COMPOSITION COMPRISING THE SAME Non-Final OA KOREA ATOMIC ENERGY RESEARCH INSTITUTE
18484738 IMMUNE CHECKPOINT SUPPRESSANT Final Rejection NIHON SIZEN HAKKOH CO., LTD.
17583207 BIOSYNTHESIS OF POLYHYDROXYBUTYRATE Final Rejection Trade Wind Biotech Co., Ltd
17751943 METHODS TO PRODUCE DEFINED, SPHERICAL, BIO-DEGRADABLE MACROPOROUS MICROCARRIER/HYDROGELS FOR CELLULAR AGRICULTURE Final Rejection Innocent Meat GmbH
17917458 USE OF BACTERIAL STRAINS LACTOBACILLUS BREVIS, LACTOBACILLUS PLANTARUM AND/OR LACTOBACILLUS PENTOSUS IN THE REDUCTION OF AN INGESTED OR ACCUMULATED AMOUNT OF PHOSPHONATES IN THE HUMAN MICROBIOTA Non-Final OA PROBIOTICAL S.P.A.
17797891 COMPOSITION USING NOVEL LACTOBACILLUS PLANTARUM KC3 STRAIN FOR PREVENTION OR TREATMENT OF IMMUNE IMPAIRMENT, RESPIRATORY INFLAMMATORY DISEASE, ALLERGY, AND ASTHMA AND USE THEREOF Non-Final OA CKD BIO CORPORATION
17746731 Bacillus strains improving health and performance of production animals Non-Final OA Adisseo France SAS
17646581 PROTEIN STABILIZED LIPOSOMES (PSL) AND METHODS OF MAKING THEREOF Non-Final OA Lipotope, LLC
17514472 IMMUNOMODULATORY COMPOSITIONS AND METHODS Non-Final OA Innate Biologics LLC
17606145 COMPOSITION CONTAINING GLUCORAPHANIN AND USE THEREOF Final Rejection SHENZHEN FUSHAN BIOTECH CO., LTD.
16966656 PD-1 VARIANT HAVING IMPROVED BINDING ABILITY TO PD-L1 Non-Final OA NEURACLE GENETICS INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month